Federated Hermes
STRO icon

Federated Hermes’s Sutro Biopharma STRO Stock Holding History

Federated Hermes’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22
Closed -$957 – 2125
2023
Q4 		$957 Sell
22
-617
-97% -$19.6K ﹤0.01% 1976
2023
Q3 		$22.2K Hold
639
– – ﹤0.01% 1756
2023
Q2 		$29.7K Sell
639
-4
-0.6% -$199 ﹤0.01% 1742
2023
Q1 		$29.7K Hold
643
– – ﹤0.01% 1785
2022
Q4 		$52K Buy
643
+331
+106% +$23K ﹤0.01% 1708
2022
Q3 		$17K Sell
312
-27,464
-99% -$1.63M ﹤0.01% 1787
2022
Q2 		$1.45M Buy
+27,776
New +$1.55M ﹤0.01% 1016
2022
Q1 		– Sell
-91
Closed -$14K – 2307
2021
Q4 		$14K Sell
91
-116
-56% -$20.8K ﹤0.01% 1903
2021
Q3 		$39K Sell
207
-2
-1% -$380 ﹤0.01% 1889
2021
Q2 		$39K Sell
209
-32,668
-99% -$6.39M ﹤0.01% 1879
2021
Q1 		$7.48M Buy
32,877
+19,697
+149% +$4.67M 0.01% 740
2020
Q4 		$2.86M Buy
+13,180
New +$2.18M 0.01% 954
2020
Q3 		– Sell
-372
Closed -$29K – 2340
2020
Q2 		$29K Buy
+372
New +$35.7K ﹤0.01% 1827

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Federated Hermes's STRO Position: Q1 2024 in Review

Federated Hermes sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 22 shares — an estimated $957 sold.

Federated Hermes first reported a position in STRO in Q2 2020 and held it in 13 quarters. The position peaked at $7.48M in Q1 2021. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

  • Federated Hermes reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
  • Federated Hermes sold 22 Sutro Biopharma shares in Q1 2024, an estimated $957.
  • Federated Hermes first reported a position in Sutro Biopharma in Q2 2020 and held it in 13 quarters.
  • Federated Hermes's Sutro Biopharma position peaked at $7.48M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.